Reaction

Subileus reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,069 reports · 63 co-occurring drugs

As of the last recalculation, Subileus appears in 2,069 FAERS reports alongside 63 co-occurring drug terms. The strongest observed disproportionality signal is RIVASTIGMINE (PRR 22.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Rivastigmine	42	22.9	22.9
Granisetron Hydrochloride	18	17.5	17.5
Teduglutide	23	17.4	17.4
Valproic Acid	50	16.3	16.4
Panitumumab	25	16.2	16.3
Metoclopramide	74	14.0	14.0
Bevacizumab	159	13.9	13.9
Granisetron	14	13.5	13.5
Levodopa	15	12.6	12.6
Aprepitant	22	12.1	12.1
Candesartan Cilexetil	29	11.2	11.2
Lactulose	42	11.2	11.2
Cetuximab	34	11.1	11.1
Oxaliplatin	78	11.0	11.0
Bisacodyl Suppositories	14	11.0	11.0
Fluorouracil Cream, 0.5%	80	10.9	10.9
Biscodyl	14	10.9	10.9
Metoclopramide Hydrochloride	80	10.8	10.8
Fluorouracil	80	10.8	10.8
Capecitabine	89	10.2	10.2
Bisacodyl	14	10.1	10.1
Oxazepam	21	9.9	9.9
Regorafenib	11	9.6	9.6
Leucovorin Calcium	18	9.5	9.6
Adalimumab-Fkjp	41	9.1	9.1
Paclitaxel (Aibumin-Bound)	70	8.8	8.8
Paclitaxel	83	8.7	8.7
Adalimumab-Aaty	40	8.7	8.7
Irinotecan Hydrochloride	11	8.6	8.7
Carboplatin	102	8.4	8.5
Fesoterodine Fumarate	9	8.4	8.4
Adalimumab-Adaz	43	8.4	8.4
Etoposide	59	8.3	8.3
Pegaspargase	10	8.3	8.3
Atezolizumab	30	7.9	7.9
Thiotepa	7	7.4	7.4
Clozapine	88	7.3	7.3
Infliximab-Dyyb	21	7.3	7.3
Mesalamine	38	6.9	6.9
Brentuximab Vedotin	7	6.9	6.9
Umeclidinium	6	6.8	6.8
Gemcitabine	26	6.7	6.7
Gefitinib	6	6.7	6.7
Quinapril Hydrochloride	5	6.4	6.4
Vedolizumab	50	6.0	6.0
Fosaprepitant Dimeglumine	8	5.9	5.9
Everolimus	29	5.8	5.8
Gemcitabine Hydrochloride	29	5.6	5.6
Azacitidine	16	5.5	5.5
Cytarabine	32	5.4	5.4
Olaparib	11	5.3	5.3
Carbidopa And Levodopa	24	5.1	5.1
Azacitidine For	9	5.0	5.0
Erlotinib Hydrochloride	6	4.8	4.8
Ado-Trastuzumab Emtansine	4	4.8	4.8
Polatuzumab Vedotin	4	4.1	4.1
Pemetrexed Disodium	15	4.0	4.0
Ustekinumab	39	3.9	3.9
Abemaciclib	7	3.5	3.5
Crizotinib	4	3.2	3.2
Encorafenib	3	3.1	3.1
Trifluridine And Tipiracil	3	2.8	2.8
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	5	1.6	1.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.